What Is Tirzepatide? GIP-Backbone Dual Agonist: Structure, Receptor Balance and Research

Tirzepatide is a 39-residue synthetic peptide constructed on a GIP scaffold that activates the receptor for glucose-dependent insulinotropic polypeptide as well as the GLP-1 receptor — the first dual incretin agonist investigated on a large scale. Nicknamed a twincretin, it is the reference tool compound whenever a laboratory wants to ask what happens when a single ligand engages two incretin receptors rather than two separate ligands doing so. We supply research-grade tirzepatide as lyophilized powder in sealed vials, for in-vitro and preclinical work only.

Clinical data in humans relate to the approved medicine built on this molecule. Those results describe a regulated pharmaceutical rather than the reference material described here, and nothing on this page constitutes a protocol for human use.

Tirzepatide defined

Tirzepatide is a linear chain of 39 amino acids carrying a C20 fatty diacid joined through a glutamate and two short ethoxy-based spacers. Its sequence comes from native GIP, not from GLP-1 — which catches out anyone who assumes a dual agonist must be a GLP-1 molecule with extra features grafted on. That is not how it was made. Designers began with the GIP scaffold and added substitutions that brought GLP-1 receptor activity onto it. The starting point has real experimental consequences: as a GIP receptor agonist tirzepatide is potent, with affinity close to native, whereas its GLP-1 receptor activity falls short of a dedicated GLP-1 analogue such as semaglutide. In other words, it is an unbalanced dual agonist, not an evenly weighted one.

Design and structure

• Scaffold. Derived from GIP(1-39) and 39 residues long — appreciably longer than the 31-residue GLP-1 analogues in the same collection.
• Aib at positions 2 and 13. Alpha-aminoisobutyric acid at position 2 prevents DPP-4 cleavage, while the second Aib stiffens the helix further and has been reported to help set the balance between the two receptor activities.
• C20 fatty diacid on Lys20. A longer lipid than semaglutide's, linked via a gamma-Glu and two AEEA spacers, which produces reversible albumin binding and the prolonged circulation described in pharmacokinetic studies.
• Amidated C-terminus. Capping the C-terminus as an amide removes a negative charge and improves resistance to carboxypeptidases.

Its identifiers are CAS 2023788-19-2, formula C225H348N48O68 and molecular weight 4813.45 Da. At roughly 4.8 kDa it ranks among the heavier molecules in the incretin range, and its mass gap compared with semaglutide is wide enough to serve as a diagnostic in a mass-spectrometric identity check.

Mechanism of action

The reported mechanism depends on simultaneously engaging two class B G-protein-coupled receptors, both of which signal through Gs. In islet beta cells, activating the GLP-1 receptor lifts cAMP and amplifies glucose-dependent insulin release. GIP receptor activation does likewise in beta cells but brings additional reported actions that GLP-1 signalling lacks: GIP receptors occur on adipocytes, where published work describes effects on lipid buffering and blood flow, and on alpha cells, where GIP has been reported to modulate glucagon secretion in a glucose-dependent way.

Two aspects of tirzepatide pharmacology appear repeatedly in the in-vitro literature. The first is signal bias: at the GLP-1 receptor it has been reported to recruit beta-arrestin only weakly compared with native GLP-1, so less receptor internalises and cAMP output persists longer — a property several groups have offered as an explanation for its potency in whole animals. The second is receptor imbalance: since potency at the GIP receptor outstrips that at the GLP-1 receptor, at low occupancy the compound behaves largely as a GIP agonist, and the GLP-1 component only becomes prominent as occupancy climbs. Any concentration-response design that overlooks this will merge two distinct pharmacologies into one curve.

Research applications

• Receptor and cell studies. cAMP accumulation and binding assays in cells expressing human GIPR and GLP-1R, beta-arrestin recruitment, imaging of receptor trafficking, and knockout or antagonist experiments intended to pin each effect to a specific receptor.
• Rodent studies. Diet-induced obesity models reporting lower food intake and altered fat mass, work on liver lipid content, brown adipose thermogenesis experiments, and receptor-knockout mice used to assign observed changes to GIPR or GLP-1R signalling. How much the GIP arm contributes remains genuinely disputed in this literature and should not be treated as resolved.
• Human trials of the approved product. Large randomised programmes in type 2 diabetes and obesity, together with published work in sleep apnoea and in heart failure with preserved ejection fraction. Once again: an approved pharmaceutical in a prescription setting, not transferable to research-grade powder.

There is a practical implication for bench design. Because the two receptor arms can be separated pharmacologically, the most informative tirzepatide experiments include at least one single-receptor comparator. Pairing tirzepatide with a pure GLP-1 receptor agonist allows the GLP-1 contribution to be subtracted from any observed effect, and adding a selective GIP receptor agonist or antagonist arm isolates what remains. Without such arms, a result from tirzepatide alone can seldom be assigned to a particular receptor — the most frequent shortcoming in published dual-agonist comparisons.

One open question drives a good deal of today's mechanistic work: is agonism or antagonism at the GIP receptor the metabolically beneficial direction? Both approaches have shown activity in preclinical models, and resolving that apparent contradiction is an active line of research.

Species differences also deserve note. GIP receptor pharmacology is less conserved across species than GLP-1 receptor pharmacology, and potency ratios obtained at rodent receptors do not always hold at the human receptor. Read papers reporting tirzepatide activity with attention to which receptor ortholog the assay used, and treat cross-species extrapolation of the GIP arm in particular as a hypothesis rather than a settled fact.

Available formats and vial sizes

The 60 mg and 100 mg vials are intended for multi-arm animal studies and assay panels, where running every condition from one lot removes a variable. For smaller receptor experiments, the 10 mg vial is usually the sensible choice. Current sizes and prices appear on the tirzepatide product page, and the broader range sits in the GLP-1 and incretin collection.

Reconstitution and storage at the bench

Reconstitution is simply a concentration calculation. Making a 30 mg vial up to 3 mL with bacteriostatic water gives 10 mg/mL (10,000 mcg/mL), so 0.05 mL of that solution contains 500 mcg of peptide. Add the diluent slowly against the vial wall, let the cake dissolve without shaking, and check the solution is completely clear before use — acylated peptides of this molecular weight readily aggregate visibly if agitated.

Keep sealed lyophilized material at minus 20 degrees Celsius, away from light and moisture; store reconstituted solution at 2 to 8 degrees Celsius and use it within the study period. Since tirzepatide vials are often large, aliquoting at the moment of reconstitution matters more here than for smaller peptides: each extra freeze-thaw cycle on a shared stock means measurable loss of purity. Our reconstitution guide covers the procedure.

Purity and reading the certificate of analysis

A certificate should carry an HPLC trace with the main-peak area percentage, a mass-spectrometric value checked against the theoretical 4813.45 Da, net peptide content, the lot number and the analysis date. For a 39-residue synthetic peptide the impurity profile is informative in its own right: deletion sequences and partially deprotected intermediates elute near the main peak, so a chromatogram with a clean baseline and clearly resolved shoulders reveals more about synthesis quality than any single headline percentage. Check that the lot on the certificate matches the lot on your vial. See how to read a peptide COA.

Regulatory position

In its pharmaceutical form, tirzepatide is an approved prescription medicine in the United States, the EU and other markets. Research-grade tirzepatide is a laboratory reference chemical for research use only, not for human consumption, and under no circumstances a substitute for a prescribed product.

Related compounds and comparisons

Its obvious comparators are the single-receptor agonist semaglutide and the triple agonist retatrutide, discussed in semaglutide vs tirzepatide and retatrutide vs tirzepatide. For duals that include the glucagon receptor, see survodutide.